Regulatory & Legal
EMA: Human medicines European public assessment report (EPAR): Viekirax (ombitasvir / paritaprevir / ritonavir) - Revision: 9 - Authorised
EMA published the approvals of changes - the sections 4.8 and 5.1 of the SmPC are updated to reflect the main results of study M14-226 (RUBY-I). In addition, the MAH took the opportunity to make a correction in the product information of Viekirax.
In an unexpected move, just before the end of 2011, ...
Improving expenditure efficiency has been, for a ver...
Your Portal Link to Mass Media Universe.
Valuable Quarterly Romanian Market Analysis.
Ask the analyst
Tailor-made advice for you